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Objective. Immune dysfunction is an important component of the disease process underlying systemic sclerosis (SSc), but the mechanisms contributing to altered immune cell function in SSc remain poorly defined. This study was undertaken to measure the expression and function of the coinhibitory receptors (co-IRs) programmed cell death 1 (PD-1), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin and mucin domain 3 (TIM-3), and lymphocyte activation gene 3 (LAG-3) in lymphocyte subsets from the peripheral blood of patients with SSc.
Methods. Co-IR expression levels on subsets of immune cells were analyzed using a 16-color flow cytometry panel. The functional role of co-IRs was determined by measuring cytokine production after in vitro stimulation of SSc and healthy control peripheral blood mononuclear cells (PBMCs) in the presence of co-IR-blocking antibodies. Supernatants from cultures of stimulated PBMCs were added to SSc fibroblasts, and their impact on fibroblast gene expression was measured. Mathematical modeling was used to reveal differences between co-IR functions in SSc patients and healthy controls.
Results. Levels of the co-IRs PD-1 and TIGIT were increased, and each was coexpressed, in distinct T cell subsets from SSc patients compared to healthy controls. Levels of TIM-3 were increased in SSc natural killer cells. PD-1, TIGIT, and TIM-3 antibody blockade revealed patient-specific roles of each of these co-IRs in modulating activation-induced T cell cytokine production. In contrast to healthy subjects, blockade of TIGIT and TIM-3, but not PD-1, failed to reverse inhibited cytokine production in SSc patients, indicating that enhanced T cell exhaustion is present in SSc. Finally, cytokines secreted in anti-TIM-3-treated PBMC cultures distinctly changed the gene expression profile in SSc fibroblasts.
Conclusion. The altered expression and regulatory capacity of co-IRs in SSc lymphocytes may contribute to disease pathophysiology by modulating the cytokinemediated cross-talk of immune cells and fibroblasts at sites of inflammation and/or fibrosis.
Systemic sclerosis (SSc) is an autoimmune connective tissue disorder characterized by external skin thickening that can progress to internal organ fibrosis in the presence of immune abnormalities (1, 2) . Autoantibodies and lymphopenia are often detected in SSc patients (2) . CD8+ T cells and CD4+ Treg cells have been shown to produce increased levels of the profibrotic cytokine interleukin-13 (IL-13) (3, 4) , while natural killer (NK) cells have been reported to be less cytotoxic and have defects in interferon-c (IFNc) production (5) . However, while differences in the cytokines produced in SSc may contribute to disease pathophysiology (6) , the mechanisms underlying these changes in immune cell cytokine production remain largely unknown. The function of T cells and NK cells is regulated by coinhibitory receptors (co-IRs) such as programmed cell death 1 (PD-1), lymphocyte activation gene 3 (LAG-3), T cell immunoglobulin and ITIM domain (TIGIT), and T cell immunoglobulin and mucin domain 3 (TIM-3) (7, 8) . Engagement of these receptors by their ligands limits cytokine production in response to stimulation of the cells by either T cell receptor (TCR) or activating NK cell receptor. Co-IRs thus play critical physiologic roles in limiting tissue damage from excessive immune activation. However, chronically increased expression of multiple co-IRs is a hallmark of immune exhaustion (9) , in which immune cells are no longer able to execute effector functions to fight chronic viral infections and cancer (10, 11) .
In autoimmunity, co-IRs are protective. Antibody blockade or genetic deletion of PD-1, TIM-3, TIGIT, and LAG-3 in mouse models of autoimmune disease, such as models of type 1 diabetes, lupus, and multiple sclerosis, all result in accelerated or exacerbated disease (7) . Treatment of cancer patients with co-IR blockade often precipitates autoimmune adverse events (12) . As a corollary, reinforcing immune checkpoints in autoimmune disease may have therapeutic benefit. In support of this, one study demonstrated correlation of an exhaustion-like phenotype, marked by an increase in co-IR expression, with fewer flares in lupus patients (10) , and the presence of TIM-3+ T cells was associated with milder forms of multiple sclerosis (13) . Moreover, in patients with SSc, the PD-1 pathway was recently found to be involved in regulating disease severity (14) .
In the present study, we determined the expression of the co-IRs PD-1, TIGIT, TIM-3, and LAG-3 on lymphocyte subsets from the peripheral blood of patients with SSc, and assessed their role in cytokine regulation and fibroblast activation. PD-1, TIM-3, and TIGIT showed increased expression in specific T cell and NK cell subsets from SSc patients. Cytokine production in the presence of co-IR-blocking antibodies against PD-1, TIM-3, and TIGIT revealed significant patient-specific variation in the function of individual co-IRs. In most subjects, however, at least one co-IR was actively suppressing cytokine production, indicative of the presence of exhausted cell populations. Multivariate analysis revealed that TIGIT and TIM-3 were functionally distinct from PD-1 in SSc patients, but not in healthy controls. Finally, changes in the cytokines produced by peripheral blood mononuclear cells (PBMCs) after TIM-3 blockade resulted in altered fibroblast gene expression.
The results of our study thus suggest that increased co-IR expression in SSc lymphocyte subsets contributes to patient-specific activities involved in the modulation of cytokine production. Suppressed and/or excessive production of specific cytokines in the local microenvironment may subsequently promote pathogenic fibrotic or inflammatory responses in connective tissue and vascular cells.
PATIENTS AND METHODS
Patients and healthy controls. All samples and clinical data were collected under a protocol approved by the Institutional Review Board at Boston University. Blood samples obtained from 30 patients with SSc and 21 healthy subjects were collected in EDTA blood collection tubes (BD Vacutainer). Classification of the diagnosis in all patients was made according to the American College of Rheumatology criteria for SSc (1) . The patients had not received immunosuppressive therapy for at least 6 months prior to the time of blood collection. Patients and healthy controls were matched according to age.
Sample collection. Blood samples were collected and PBMCs were isolated on the same day. To do this, Lymphoprep (Stem Cell Technologies) was underlaid under the blood, and PBMCs were separated by density-dependent centrifugation. PBMC samples were frozen in 50% RPMI medium (10% fetal bovine serum [FBS] , 1% nonessential amino acids, 1% HEPES, 1% penicillin/streptomycin, 1% sodium pyruvate, 0.1% b-mercaptoethanol) with 40% FBS and 10% DMSO, and then stored in liquid nitrogen.
Flow cytometry analysis. PBMCs were thawed, stained, and analyzed in a manner as previously reported (15) , using a BD FACSAria SORP with FACSDiva software (BD Biosciences). Expert-guided gating of the cells, utilizing FlowJo version 10 and Cytobank, was performed by 3 independent analysts (MF, ACB, and JES-C). A tSNE dimensionality reduction was performed using a Cytobank platform with the following parameters: input of 500,000 single, live, CD14À/CD19À events; clustering channels (all arcsin-transformed) for CD3, CD4, CD8, CD25, CD127, CD45RO, cd TCR, CD16, CD56, Va24, and CD1d-PBS57; total number of iterations 3,000; theta 0.5; perplexity 30.
In vitro stimulation of PBMCs with allogeneic monocyte-derived dendritic cells (DCs). Monocyte-derived DCs were produced after selection of CD14+ cells (Stem Cell Technologies) from PBMCs isolated from a buffy coat, in accordance with the manufacturer's instructions. CD14+ monocytes were cultured for 5 days in 7.5 ng/ml IL-4 (BD Biosciences) and 20 ng/ml granulocyte-macrophage colonystimulating factor (Miltenyi Biotec). On day 4, 1 ng/ml of Escherichia coli lipopolysaccharide (Sigma) was added to the cultures to mature the DCs. Previously frozen PBMCs from patients and healthy controls were thawed and cocultured with allogeneic DCs at a 1:10 ratio of DCs to PBMCs with 5 lg/ml of blocking antibodies, including anti-PD-1 (clone J116; eBioScience), anti-TIGIT (clone MBSA43; eBioScience), anti-TIM-3 (clone F38-2E2; BioLegend), or isotype control (clone P3.6.2.8.1; eBioScience), in the presence of human Fc Block (BD Biosciences). Cultures were kept in an atmosphere of 37°C and 5% CO 2 for 5 days, and supernatants were collected and stored at À80°C.
Multiplex cytokine analysis. Supernatants from in vitro stimulation cultures were analyzed using a 14-plex cytokine bead array kit (Milliplex MAP; Millipore) on a Luminex 100 platform, to determine cytokine concentrations. A human Th17 Magnetic Bead Panel (Milliplex MAP HTH17MAG-14K-14) was used to detect concentrations of IFNc, IL-10, IL-13, IL-22, IL-9, IL-33, IL-2, IL-21, IL-4, IL-23, IL-5, IL-6, IL-27, and tumor necrosis factor (TNF). Data were analyzed using Milliplex Analysis software, version 5.1. The standard curve was determined by interpolation from corresponding standards. IL-22 and IL-33 were excluded from these analyses because they were below the limit of detection. Undetectable values were given an arbitrary value of 0. Values were clustered using Gene Cluster version 3.0 and then normalized, mean centered, and clustered by complete linkage, followed by visualization in JavaTree.
Fibroblast cell culture. SSc human dermal fibroblasts were grown to 80% confluence in Dulbecco's modified Eagle's medium with 10% FBS, and 2.5 9 10 5 cells were serum-starved overnight with medium containing 0.5% FBS. Next, the medium was replaced with 50% supernatant from in vitro-stimulated PBMC cultures and 50% RPMI medium containing 10% FBS. As controls, additional cultures were set up with 10 ng/ml transforming growth factor b1 (TGFb1; R&D Systems), 30 ng/ ml IL-13 (R&D Systems), or no cytokines. Cells were incubated for 24 hours at 37°C, washed with phosphate buffered saline, and lysed with RLT buffer (Qiagen). RNA was collected with an RNeasy Mini kit (Qiagen).
Gene expression analysis. For analyses of gene expression, 100 ng of RNA was added to NanoString polymerase chain reaction tubes, followed by the addition of 20 ll Reporter CodeSet diluted in Buffer CodeSet and 5 ll of Capture ProbeSet reagent (NanoString Technologies). Samples were placed in an MJ Mini thermocycler (Bio-Rad) at 67°C and processed in an nCounter Prep Station (NanoString Technologies). Expression values for each gene were normalized to those for a variety of housekeeping genes, following a previously described method (16) . Values were clustered using the Gene Cluster program (version 3.0) and normalized, mean centered, and clustered by complete linkage, followed by visualization in JavaTree.
Mathematical modeling. Partial least squares discriminant analysis (PLSDA) was conducted in MatLab using the PLS Toolbox (Eigenvector Research). Data were normalized along each parameter by Z score before application of the algorithm. Cytokines or genes with non-zero values in fewer than one-half of the subjects were excluded from these analyses. Cross-validation was performed with one-fifth of the relevant data set, and the number of latent variables (LVs) was chosen to minimize cross-validation error. Model confidence was calculated by randomly permuting the response variables 100 times and rebuilding the model to form a distribution of error for random models. We then compared our model to this distribution using the Mann-Whitney U test. The importance of each parameter to the model prediction was quantified using a variable importance in projection (VIP) score. A VIP score of >1 (representing above average contribution) was considered important for model performance and prediction. The LASSO method (Mathworks; Matlab) was applied for variable selection in the gene expression data to determine the minimum gene set necessary for distinguishing treatment groups. K-fold cross-validation was utilized to optimize the set of gene parameters such that the error of the resulting model was minimized.
Statistical analysis. Groups were compared by t-tests, which were performed using the R function t.test, with correction for multiple comparisons made using R function p.adjust. The fdr parameter was used for false discovery rate adjustment.
RESULTS
Increased co-IR expression in T and NK cell subsets in SSc PBMCs, as revealed by immunophenotyping. While the expression of co-IRs, as a hallmark of T cell exhaustion, has been associated with disease outcome in several autoimmune diseases, including lupus and type 1 diabetes (10), an extensive comparison of the expression of multiple coIRs between SSc patients and healthy subjects has not been performed. Therefore, we isolated PBMCs from SSc patients and age-matched healthy controls (Table 1) and stained the cells with a 16-color flow cytometry antibody panel to characterize expression of 4 co-IRs on various immune cell subsets simultaneously (15) . Importantly, only patients who were not taking immunosuppressants were selected for our study, to rule out any role of immune-modulating drugs on expression levels. * NA = not applicable; dcSSc = diffuse cutaneous systemic sclerosis; lcSSc = limited cutaneous systemic sclerosis; ILD = interstitital lung disease; PAH = pulmonary arterial hypertension. † For 7 patients, no score was reported. high NK cells was determined. Each symbol represents an individual subject; bars show the mean AE SEM. Differences between groups were determined using the t-test with false discovery rate adjustment. * = P ≤ 0.05; ** = P ≤ 0.01. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40399/abstract.
Twelve distinct immune cell types could be identified in analyses applying an automated viSNE algorithm that blindly clusters cell subsets using fluorescence data ( Figure 1A) . Expression of the co-IRs PD-1, TIM-3, TIGIT, and LAG-3 showed significant cell-type specificity, with PD-1 mostly expressed in CD45RO+ memory T cells, TIGIT in T cells and NK cells, and TIM-3 predominantly in NK cells ( Figure 1B ). LAG-3 showed an overall low expression.
To compare co-IR expression on blood lymphocyte subsets between SSc patients and healthy controls, we defined 10 distinct subsets of T and NK cells using a manual gating strategy (further details available upon request from the corresponding author). After exclusion of dead cells as well as CD19+ B cells and CD14+ monocytes, CD3+ T cells were further divided into CD4+CD8À T helper cells, CD4ÀCD8+ cytotoxic T cells, cd T cells, and invariant NK T (iNKT) cells. Within the CD4+ T cells, high expression levels of CD25 and low levels of CD127 were used to delineate a population enriched in regulatory T cells, hereinafter referred to as Treg cells (17, 18) . Since the CD25+CD127 low phenotype does not equate 100% to FoxP3+ Treg cells, it is critical to consider that changes in co-IR expression within this population may also represent a small subset of activated effector CD4+ T cells. CD4+ and CD8+ T cell subsets were subdivided into CD45RO+ memory and CD45ROÀ naive subsets (19) . It is important to note that we did not observe any differences in the frequencies of the major T cell types between SSc patients and healthy controls, except for an increase in CD25+CD127À Treg cells in the SSc group. Interestingly, the Treg cell subset showed a reduction in cells with a CD45RO+ effector/memory phenotype in SSc patients (results available upon request from the corresponding author).
For CD4+ conventional T cells, CD4+ Treg cells, and CD8+ T cells, the expression of PD-1, TIGIT, TIM-3, and LAG-3 was determined within the CD45RO+ effector/memory population, since naive T cells typically express low levels of these receptors (representative dot plots of co-IR staining are available upon request from the corresponding author). In SSc patients, the numbers of PD-1-expressing cells within the Treg cell subset and within cd T cells were significantly increased compared to those from healthy subjects, while no differences in PD-1 expression were observed on CD8+ T cells, iNKT cells, or NK cells ( Figure 1C) . The difference in PD-1 expression on CD4+ conventional T cells did not reach statistical significance after false discovery rate analysis, but strongly trended toward an increase in SSc patients (P = 0.054) ( Figure 1C) . (Figure 1D) .
TIM-3 showed low expression levels on all T cell subsets, confirming the findings from viSNE analysis, and no differences between healthy controls and SSc patients were observed ( Figure 1E ). As noted above, TIM-3 was strongly present on NK cells and further increased on the CD16+CD56 medium cell subset in SSc patients. LAG-3 was minimally present on all analyzed cell subsets, and there were no noteworthy differences between healthy subjects and SSc patients ( Figure 1F ). Not surprisingly, co-IRs were expressed at lower levels in CD45ROÀ naive conventional T cells, Treg cells, and CD8+ cells, although some differences in SSc patients compared to healthy controls were still apparent (results available upon request from the corresponding author).
Finally, we performed a separate analysis of patients with high percentages of Treg cells. We determined that the presence of significantly more Treg cells (or CD25+CD127 low activated effector cells) in 7 patients could not be attributed to SSc disease type (limited versus diffuse) or the presence or absence of lung and skin involvement (results not shown). Intriguingly, patients with high Treg cell percentages also had . Subject-specific activities of coinhibitory receptors in controlling lymphocyte cytokine production. PBMCs from SSc patients and healthy controls were stimulated with dendritic cells from a healthy donor in the absence or presence of anti-PD-1, anti-TIGIT, or anti-TIM-3 blocking antibodies, and supernatants were analyzed with a 14-cytokine multiplex assay. Bar graphs show the amount (in pg/ml) of each of the indicated cytokines produced by the cells from individual healthy subjects and SSc patients. The broken vertical line indicates the level of total cytokine produced in the isotype control cultures. IFNc = interferon-c; IL-21 = interleukin-21; TNF = tumor necrosis factor (see Figure 1 for other definitions).
increased co-IR expression (results available upon request from the corresponding author), potentially suggestive of a more "activated" disease environment in these patients, which could lead to Treg cell expansion and enhanced co-IR expression.
Increased frequency of T lymphocytes coexpressing PD-1 and TIGIT in SSc patients. One hallmark of exhausted T cells is the accumulated expression of multiple co-IRs on the cell surface (9) . Comprehensive co-IR signature analysis revealed that CD4+ conventional T cells and Treg cells from SSc patients contained an increased frequency of PD-1+TIGIT+ double-positive cells compared to those from healthy subjects (Figures 2A-D) . In NK CD56 medium cells, coexpression of TIGIT and TIM-3 showed a trend toward increased presence in SSc patients compared to healthy controls (results not shown). The increased presence of T cells expressing combinations of co-IRs in SSc patients suggests that immune dysfunction and T cell exhaustion were increased in those patients. Perhaps surprisingly, this augmented exhaustion signature, as well as the increased levels of single co-IR-positive cell populations (as described above), did not correlate with disease duration in SSc patients (results not shown). The striking exhaustion phenotype, however, prompted us to investigate the functional role of co-IRs in the activation of T cells from SSc patients.
Patient-specific activity of PD-1, TIGIT, and TIM-3 in controlling T cell cytokine production. To directly test whether co-IRs differentially regulate T cell responses in SSc patients and healthy subjects, we designed an assay using monocyte-derived DCs from a healthy donor as an allogeneic stimulus in a mixed lymphocyte reaction (MLR). This assay requires cognate T cell-DC interactions for T cell activation, thereby facilitating physiologic engagement of co-IRs on the T cells with their ligands on the DCs (20) . For this reason, an MLR is often used to test the functionality of novel checkpoint inhibitors for cancer immunotherapy (21) (22) (23) . By using the same DC donor to stimulate responders, we could eliminate the possibility that differing amounts of inhibitory receptor ligands present on the DCs would be a potential confounding variable. Co-IR-blocking antibodies against PD-1, TIGIT, and TIM-3 were added to the MLR to prevent the binding of ligands to the receptors.
In the first set of experiments, we confirmed that antibody treatment did not affect the viability or ratios of the CD4+ and CD8+ T cell subsets in the MLR cultures (results available upon request from the corresponding author). We next collected supernatants from MLR cultures, and 14 cytokines were measured using a multiplex platform. As expected, the amounts and types of cytokines produced by individual subjects showed significant variability (Figure 3 ). Nevertheless, 2 distinct profiles could be readily observed: 1) subjects who showed a response dominated by the proinflammatory cytokines IFNc, IL-6, and TNF (healthy control subjects 1-4 and SSc patients 1-3 in Figure 3) , and 2) subjects with a more diverse cytokine response and increased presence of Th2 cytokines (healthy control subject 5 and SSc patients 4-6 in Figure 3) .
In most cases, co-IR blockade did not appear to selectively promote the production of specific cytokines, and therefore none of the co-IR-blocking antibody treatments led to dramatic changes in the composition of patient-specific cytokine profiles (Figure 3 ). In 4 of 5 healthy control subjects and 4 of 6 SSc patients, at least 2 of the co-IR-blocking antibodies increased the total amount of cytokines produced. In both healthy subjects and SSc patients, PD-1 appeared to be the strongest regulator of cytokine secretion ( Figure 3 and Figure 4A) . The role of TIGIT and TIM-3 was modest in SSc patients, whereas in most healthy subjects, TIGIT and/or TIM-3 were potent secondary regulators of total cytokine secretion ( Figure 4A) .
Interestingly, there was significant patient-specific variation in the cytokine-regulating activities of co-IRs. This experiment demonstrated that co-IR expression in SSc PBMCs is not exclusively a marker of a dysfunctional immune system, but rather, interactions of co-IRs with their ligands can actively regulate T cell effector functions and thus may play a role in the T cell-dependent pathogenic processes of SSc.
To establish whether co-IR blockade during the MLR cultures differentially affected the cytokine response of immune cells between SSc patients and healthy subjects, the large data set was analyzed using advanced bioinformatics and mathematical modeling. Unsupervised hierarchical clustering of cultures from subjects with various treatments and cytokines resulted in individual donors, rather than treatment groups, clustering together, masking any indication of potential effects of the blocking antibodies on cytokine production (results available upon request from the corresponding author). Therefore, to determine whether the activities of PD-1, TIGIT, and TIM-3 in SSc patients and healthy subjects could be differentiated, we performed PLSDA. The PLSDA method is a mathematical analysis method that uses LVs to determine which parameters contribute to causing the greatest difference between samples. PLSDA is useful when the behaviors of multiple analytes of interest, in this case cytokines, are known to be interdependent and can reveal combinations of cytokines whose fluctuation, as a group, maximally correlates with the anti-co-IR antibody treatments (24, 25) . Figure 4 . Cytokine production is modulated by coinhibitory receptor (co-IR)-blocking antibodies against PD-1, but not those against TIGIT or TIM-3, in SSc PBMCs. A, Fold changes in the levels of total cytokines (relative to values in isotype controls) after co-IR blockade are shown. Each symbol represents an individual healthy control or SSc patient; bars show the mean AE SEM. B-D, Multiplex cytokine data were subjected to partial least squares discriminant analysis to identify variations in patterns of cytokine production (normalized to isotype control values) after blockade with co-IR-blocking antibodies. Graphs show data points from each co-IR-blocking antibody culture condition with cells from SSc patients (B) and healthy controls (C), mapped onto 3-dimensional latent variable (LV) space and connected with lines that meet at their centroid. D, The contribution of each cytokine from the SSc mixed lymphocyte reaction cultures to LV1 is shown, with asterisks denoting cytokines with a variable importance in projection score >1, indicating greater than average contribution. IFNc = interferon-c; IL-10 = interleukin-10; TNF = tumor necrosis factor (see Figure 1 for other definitions). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/ doi/10.1002/art.40399/abstract.
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Cytokine levels in each treatment group were normalized relative to those in isotype-treated controls, to account for the large differences in total cytokine produced between subjects. The samples were then mapped onto 3-dimensional LV space and connected with lines that meet at their centroid. In SSc patients, our analysis showed that profiles of cytokine secretion differed between anti-PD-1-treated cells and anti-TIM-3-treated and anti-TIGIT-treated cells ( Figure 4B ), with a model confidence of 88%; this distinction was not found in samples from healthy controls ( Figure 4C ). The PLSDA model was unable to show any differences in anti-TIGIT or anti-TIM-3 effects on cytokine production between healthy controls and SSc patients.
Multiple cytokines contributed to LV1, which separated the effects of anti-PD-1 treatment from those of anti-TIGIT and anti-TIM-3 treatment in SSc patients ( Figure 4D ). Increased overall production of IL-10, IL-13, IL-2, IL-21, and IL-4 in the anti-PD-1-treated SSc samples contributed most significantly to the distinction, as determined by VIP score. This analysis thus strengthens the conclusion that in SSc patients, PD-1 continued to exert its normal function of actively inhibiting T cell cytokine production, but the TIGIT and TIM-3 pathways, while actively controlling cytokine secretion in healthy controls, became defective or refractory to reversal in SSc. Such a separation between the functionality of PD-1 on the one hand, and TIGIT/ TIM-3 on the other hand, has not been previously demonstrated in a human autoimmune disease.
Modulation of SSc fibroblast activation following the alteration of T cell cytokine production by co-IR blockade. Much of the pathogenesis of SSc is driven by fibrosis in target organs. It is thought that pathogenic fibroblasts produce large amounts of collagen, leading to loss of cellularity and elasticity in the skin and internal organs (26) . To explore whether antibody blockade of co-IRs on T cells could have a potential effect on this cell type, we cultured SSc primary fibroblasts for 24 hours with the supernatants collected from MLR cultures (the same cultures as shown in Figure 3 ). Fibroblasts were washed and RNA was isolated for NanoString analysis of genes previously described to be important in SSc disease pathogenesis (16) . Interestingly, hierarchical clustering revealed that the 2 main clusters are largely driven by the 2 distinct cytokine signatures identified in Figure 3 : the "proinflammatory" group and the "diverse/Th2" group (further details available upon request from the corresponding author). Within these 2 groups, donor-specific patterns of gene expression appeared to be the most similar. Since our data demonstrated that treatment with co-IR-blocking antibodies mostly resulted in quantitative, rather than qualitative, changes in cytokine production, it is perhaps not surprising that supernatants from treated cultures did not lead to uniformly clustered changes in the patterns of basic fibroblast gene expression.
We next examined whether multivariate mathematical modeling was capable of distinguishing the effects of anti-co-IR treatment on fibroblast gene expression AEBP1  ANGPTL4  CNN2  COL10A1  COL11A1  COL4A2  COL8A1  COMP_2  CTGF  IFI16  IFNGR1  IL4R  MICAL2  PDPN  PLEKHO2  POSTN  PPP2R1B  SHISA5  STC2 after exposure to culture supernatants. Feature selection using the LASSO algorithm was performed, resulting in narrowing of our gene set from 53 genes to 21 genes. Subsequently, PLSDA was applied to identify patterns of fibroblast gene expression that differentiated the treatment groups. Surprisingly, we found that fibroblasts treated with supernatants from anti-TIM-3-treated MLRs, both those derived from SSc samples and those derived from healthy control samples, had a distinctly modified gene expression profile as compared to the anti-PD-1 and anti-TIGIT treatment groups ( Figure 5A ). This distinct gene expression profile from the anti-TIM-3 group showed separation based on LV1 ( Figure 5B ). Since we observed that TIM-3 did not strongly regulate the 12 cytokines measured in SSc lymphocytes (as shown in Figure 3 and Figures 4A and B) , it is likely that an unknown factor, induced after TIM-3 blockade, is an important regulator of SSc fibroblast gene expression. Importantly, the main drivers of LV1 were profibrotic genes, suggesting that TIM-3 might play a protective role in SSc fibrosis. Contrary to that seen with anti-TIM-3 treatment, anti-PD-1 treatment did not appear to drive gene expression changes in fibroblasts, suggesting that PD-1 mostly controls the amount of cytokines produced, without significantly changing the composition of the supernatants.
DISCUSSION
In this study, we analyzed the expression and function of the co-IRs PD-1, TIM-3, TIGIT, and LAG-3 in SSc PBMCs. PD-1 and TIGIT are increased and coexpressed on multiple T cell subsets from SSc patients, while TIM-3 is increased on the cytotoxic CD16+CD56 medium subset of NK cells. Co-IRs play distinct roles in regulating the production of cytokines, and their functionality differed significantly between individual donors. Importantly, TIGIT and TIM-3, but not PD-1, showed reduced activity in SSc patients compared to healthy controls. Our observations thus support a cell-specific altered expression pattern of co-IRs in SSc immune cells, rather than a broad up-regulation of these receptors. Moreover, co-IRs play complex and patientspecific roles in the regulation of cytokine production, a finding with potential implications for achieving a better understanding of this heterogeneous disease.
SSc is a poorly understood autoimmune disorder that produces extreme reduction in quality of life, and the 10-year survival rate in patients with SSc currently averages 50% (27) . Patients have few treatment options, and a greater understanding of the underlying immunologic mechanisms of the disease is needed to assess the feasibility of developing immunotherapies. While many studies have focused on understanding aberrant fibroblast differentiation in SSc, there is also evidence that immune cells and the cytokines they produce play a critical role in fibrosis. In many fibrotic diseases, it is wellestablished that Th2-type immune responses, producing IL-4 and IL-13, promote fibrosis (28) . T cell-derived TGFb may contribute as well (29) . In SSc, however, robust evidence of a critical role of bona fide Th2 cells remains limited (30) . CD8+ T cells may also be a source of IL-13, as was demonstrated by Fuschiotti et al in SSc peripheral blood (4) and skin (31) . One intriguing study demonstrated that skin Treg cells can produce IL-4 and IL-13, possibly contributing to a fibrotic phenotype (5) . This finding, combined with studies indicating that the numbers of bona fide FoxP3+ Treg cells are reduced in the skin of SSc patients (32, 33) , suggests that Treg cell deficiencies play a role in SSc. It would be of interest to determine whether the specific reduction in CD45RO+ effector/memory Treg cells that we observed in SSc blood would correlate with the reported decrease in tissue-resident Treg cells. A number of recent studies have indicated that Th17 cells are present in SSc and may contribute to the disease process (34, 35) . Taken together, the findings in these studies underscore the need for a better understanding of the regulatory mechanisms underlying the potential profibrotic and proinflammatory functions of various T cell subsets in SSc.
Co-IRs such as PD-1, TIM-3, LAG-3, and TIGIT are an important class of molecules controlling T cell effector responses. Our finding that these receptors are aberrantly expressed in SSc patients is consistent with the general trend of increased levels of these receptors in other rheumatic diseases. However, the co-IR expression patterns on various lymphocyte subsets show considerable disease-dependent variation. For example, the levels of PD-1 were found to be increased in CD4+ and CD8+ T and NK cells from lupus patients (36, 37) and in CD3+ T cells from patients with psoriatic arthritis (38) , whereas in the present study, in patients with SSc, PD-1 was only significantly enhanced in Treg cells and cd T cells ( Figure 1C ). In addition, serum levels of soluble forms of PD-1, and its ligand PD-L2, were recently shown to be elevated in SSc (14) .
Li et al observed increased levels of TIM-3 on CD4+ and CD8+ T cells in the peripheral blood of patients with rheumatoid arthritis (39), whereas our study showed no changes in TIM-3 in SSc T cell subsets, but did show an increase in NK cells ( Figure 1E ). In lupus patients, the levels of TIGIT were found to be up-regulated on CD4+ T cells but reduced in CD8+ T cells, NK cells, and Treg cells (40) , an expression pattern that does not match with our observations in patients with SSc ( Figure 1D ). Deciphering the origin and functional consequences of these differences constitutes an important future research direction.
Co-IRs have been demonstrated to play critical functional roles in in vivo models of autoimmune disorders (7) and in chronic viral infections and cancer (9) . In HIV and cancer, increased expression of PD-1 and the coexpression of multiple co-IRs is linked with a corresponding decrease in the effector function of T cells (9), a state described as T cell exhaustion. Blocking co-IRs can restore effector function, as has been shown in successful immunotherapy for cancer (41, 42) . However, epigenetic mechanisms dictating exhaustion can provide a barrier to lymphocyte rejuvenation (43) . Our findings showing that anti-TIGIT and anti-TIM-3 antibody blockade were largely ineffective in enhancing cytokine production in PBMCs from SSc patients, and that SSc patients had increased numbers of PD-1+TIGIT+ double-positive T cells, suggest that a more robust state of T cell exhaustion, perhaps epigenetically controlled, is present in SSc patients compared to healthy controls.
Our antibody blocking experiments revealed that PD-1 played the most dominant role in modulating cytokine secretion. PD-1 has been extensively characterized as a co-IR that limits the production of cytokines in immune cells. It is therefore feasible that increased PD-1 expression in SSc patients represents a regulatory mechanism that attempts to limit tissue damage. However, absence of the ligands engaging PD-1 in the tissue microenvironment may preclude successful engagement of this pathway.
Alternatively, PD-1, TIM-3, and TIGIT may suppress some T cell cytokines, but not others, leading to subtle skewing of cytokine profiles. Such changes in cytokine signatures due to aberrant expression of combinations of co-IRs and, perhaps, their ligands in fibrotic tissues may impinge on disease processes. In support of this hypothesis, our data show that co-IR blockade during an in vitro immune response provokes changes in soluble factors that can have an impact on fibroblast gene expression. In some cases, these changes may be attributed to the presence of specific cytokines that have known activities in fibroblasts. IL-13, for example, is a potent inducer of collagen production (44) . However, one intriguing possibility, revealed by mathematical modeling, was that TIM-3 modulated the production of unidentified soluble factors that had a distinct effect on SSc fibroblast gene expression. One obvious candidate to initiate these changes would be the profibrotic cytokine TGFb, but recombinant TGFb alone was not able to recapitulate the gene expression profile induced by any of the co-IR blocking antibodies (results not shown).
In summary, our study documents the fact that SSc patients express co-IR signatures reminiscent of immune cell exhaustion. Our findings from functional analysis and mathematical modeling of the impact of these co-IRs on disease-relevant cytokine production and fibroblast gene expression suggest that these co-IR pathways play a role in the pathophysiology of SSc and may be amenable targets for therapy.
